Menu
Back to Journals » Vascular Health and Risk Management » Volume 6
Advances in the treatment of Raynaud’s phenomenon
Authors Levien T
Published 11 March 2010 Volume 2010:6 Pages 167—177
DOI https://doi.org/10.2147/VHRM.S4551
Review by Single anonymous peer review
Peer reviewer comments 2
Terri L Levien
Drug Information Pharmacist and Clinical Associate Professor, College of Pharmacy, Washington State University Spokane, WA, USA
Abstract: Raynaud’s phenomenon is a common condition characterized by vasospasm of the digital arteries and resulting cyanosis and redness. It often does not require pharmacologic management, but in some cases symptoms are severe and pharmacologic management is necessary. Calcium channel blockers are often used first-line, but in some patients are ineffective. Patients with severe symptoms or intolerance to available therapies have prompted exploration of alternative therapies, including endothelin antagonists, phosphodiesterase-5 inhibitors, antioxidants, newer vasodilators, statins, and botulinum toxin. These newer therapies provide the focus for this review.
Keywords: Raynaud, iloprost, bosentan, phosphodiesterase-5 inhibitors
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.